Prolonged continuous targeting may intensify the emergence of resistance mechanisms and carries the risk of continuous drug toxicity; intermittent targeting may allow for the mutant BRAF subpopulation of cells to regrow to induce drug-resistant tumor progression. Here, BRAF is linked to neoplasm.